MDWD
MediWound Ltd. (MDWD)
Healthcare • Biotechnology • $13.29 • MCap: 171,577,600
🌐
https://www.mediwound.com • MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Buy Decision Core
Total Score
28
Business Quality
1
Financial Strength
9
Growth Outlook
1
Momentum
2
Price Action
Current
13.29
52W High
19.69
52W Low
12.61
Above 50DMA
14.00 (-5.07%)
Above 200DMA
16.25 (-18.21%)
Relative Strength
Relative Strength
-0.16
RS 3M
-0.06
RS 6M
-0.22
RS 9M
-0.25
RS 12M
-0.18
Fundamentals
Revenue Growth
-0.46%
Earnings Growth
0%
ROE
-0.72%
ROA
-0.29%
Valuation
PE (Fwd)
-5.80
PEG
0
P/B
4.81
Upside
124.48%
Risk
Beta
0.14
Short %
0.14
Risk Score
0
Analyst
Rating
none
Target
29.83
Beta
0.14
Analysts
0
Total Score
28
Upside
124.48%
Relative Strength
-0.16
Beta
0.14
Why Buy?
- PEG Ratio below 1 (attractive valuation)
- Analyst upside exceeds 15%
Key Risks
- Revenue growth is negative
- Negative ROE
- Weak long-term relative strength
Score Breakdown
Business
1
1
Financial
9
9
Growth
1
1
Valuation
9
9
Risk
2
2
Momentum
2
2
Technical
52W High: 19.69
52W Low: 12.61
Above 50DMA: -5.07%
Above 200DMA: -18.21%
Valuation
Forward PE: -5.80
PEG: 0
P/B: 4.81
Upside: 124.48%
Risk
Beta: 0.14
Short Float: 0.14%
ROE: -0.72%
ROA: -0.29%